---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-034574"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2025-03-06T23:59:59+00:00"
generated_at: "2026-05-25T07:11:42.449175+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology Q4 net loss $29.2M; cash $131.3M; evorpacept data positive; workforce cut

## Summary
- GAAP net loss Q4 2024: ($29.2M) or ($0.55)/share, improved from ($45.5M) or ($0.93)/share in Q4 2023.
- Cash & equivalents $131.3M as of Dec 31, 2024; expects cash runway into Q4 2026 after ~30% workforce reduction.
- ASPEN-06 Phase 2: evorpacept combo cORR 48.9% vs 24.5% control in HER2+ gastric cancer; median DOR 15.7 vs 9.1 months.
- Leadership changes: appointed CBO, CMO, CFO; founder Jaume Pons steps down as President, becomes Senior Scientific Advisor.
- Upcoming catalysts: ASPEN-03/04 HNSCC topline data Q2 2025; regulatory guidance on gastric cancer path Q2 2025.

## SEC filing metadata
- accession: 0000950170-25-034574
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2025-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000095017025034574/0000950170-25-034574-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000095017025034574/alxo-20250306.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-034574
- JSON: https://secwatch.observer/filing/0000950170-25-034574.json
- Plain text: https://secwatch.observer/filing/0000950170-25-034574.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.